1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med, 2021, 18(3): 900-909.
|
3. |
Wang H, Mao X. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des Devel Ther, 2020, 14: 2423-2433.
|
4. |
Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res, 2020, 26(12): 2838-2848.
|
5. |
Yao FF, Zhang Y. A review of quantitative diffusion-weighted MR imaging for breast cancer: Towards noninvasive biomarker. Clin Imaging, 2023, 98: 36-58.
|
6. |
张靖, 宋君, 徐卫云, 等. MRI检查预测乳腺癌新辅助化疗后病理完全缓解的准确性分析. 中国普外基础与临床杂志, 2020, 27(8): 975-979.
|
7. |
张玉, 袁权, 汤增辉, 等. ADC值联合18F-FDG PET/CT最大标准摄取值对乳腺癌新辅助化疗疗效的预测价值. 放射学实践, 2022, 37(5): 550-555.
|
8. |
毛婷, 杨洋, 郝翠, 等. 采用18F-FDG PET/CT预测乳腺癌新辅助化疗治疗疗效的可行性研究. 中国CT和MRI杂志, 2022, 20(10): 64-65.
|
9. |
Bhargava R, Beriwal S, McManus K, et al. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. Appl Immunohistochem Mol Morphol, 2011, 19(3): 218-225.
|
10. |
Zapater-Moros A, Díaz-Beltrán L, Gámez-Pozo A, et al. Metabolomics unravels subtype-specific characteristics related to neoadjuvant therapy response in breast cancer patients. Metabolomics. 2023, 19(7): 60. doi: 10.1007/s11306-023-02024-8.
|
11. |
Hu G, Ding Q, Zhong K, et al. Low pretreatment prognostic nutritional index predicts poor survival in breast cancer patients: A meta-analysis. PLoS One, 2023, 18(1): 0280669. doi: 10.1371/journal.pone.0280669.
|
12. |
Xiang M, Zhang H, Tian J, et al. Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer. Oncol Lett, 2022, 24(6): 432. doi: 10.3892/ol.2022.13552.
|
13. |
Bonet C, Crous-Bou M, Tsilidis KK, et al. The association between body fatness and mortality among breast cancer survivors: results from a prospective cohort study. Eur J Epidemiol, 2023, 38(5): 545-557.
|
14. |
Trestini I, Caldart A, Cintoni M, et al. Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer. Nutrition, 2023, 105: 111858. doi: 10.1016/j.nut.2022.111858.
|
15. |
Massa C, Karn T, Denkert C, et al. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. Immunother Cancer, 2020, 8(2): e001261. doi:10.1136/ jitc- 2020-001261.
|
16. |
Yang G, Liu P, Zheng L, et al. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer. Front Surg, 2022, 9: 1004687. doi: 10.3389/fsurg.2022.1004687.
|
17. |
Kusama H, Kittaka N, Soma A, et al. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer. Breast Cancer, 2023, 30(6): 1085-1093.
|
18. |
高晓丽, 吴斌. 系统性炎症指标与局部晚期乳腺癌新辅助化疗后病理完全缓解的关系. 中国普外基础与临床杂志, 2023, 30(4): 443-449.
|
19. |
Gu Q, Zhao J, Liu Y, et al. Association between the systemic immune-inflammation index and the efficacy of neoadjuvant chemotherapy, prognosis in HER2 positive breast cancer—a retrospective cohort study. Gland Surg, 2023, 12(5): 609-618.
|
20. |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2022 . 第1版. 北京, 人民卫生出版社, 2022: 19-20.
|
21. |
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3. 2022, NCCN Clinical Practice Guidelines in Oncology. Natl Compr Canc Netw, 2022, 20(6): 691-722.
|
22. |
中国肥胖问题工作组数据汇总分析协作组. 我国成人体重指数和腰围对相关疾病危险因素异常的预测价值: 适宜体重指数和腰围切点的研究. 中华流行病学杂志, 2002, 23(1): 5-10.
|
23. |
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 1988, 44(3): 837-845.
|
24. |
饶玲艳, 黄凯明, 任蓓蓓, 等. 全身炎症反应指数对乳腺癌新辅助化疗患者病理完全缓解的预测作用. 浙江医学, 2023, 45(10): 1079-1083.
|
25. |
Li S, Zhang Y, Zhang P, et al. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis. Breast. 2022, 66: 97-109.
|
26. |
van den Ende NS, Nguyen AH, Jager A, et al. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci, 2023, 24(3): 2969. doi: 10.3390/ijms24032969.
|
27. |
孙苗苗, 蒋燕妮, 宋国新, 等. 乳腺癌新辅助化疗前后免疫标志物表达变化及预后. 中华病理学杂志, 2021, 50(5): 482-487.
|
28. |
刘嘉伟. 乳腺癌新辅助治疗前后生物标志物表达与疗效和预后的相关性研究. 南方医科大学, 2023. doi:10.27003/d.cnki.gojyu.2023.000443.
|
29. |
鞠仙莉, 袁修学, 阎红琳, 等. 乳腺癌新辅助化疗疗效预测指标的研究进展. 中国组织化学与细胞化学杂志, 2023, 32(3): 323-327.
|
30. |
Dan J, Tan J, Huang J, et al. Early changes of platelet-lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer. Mol Clin Oncol, 2023, 19(5): 90. doi: 10.3892/mco.2023.2686.
|
31. |
林佳雯, 李淑琴, 卫姣飞. 肿瘤相关中性粒细胞和中性粒细胞与淋巴细胞比值对乳腺癌新辅助化疗疗效及预后的评估价值. 解放军医学杂志, 1-14 [2024-04-01]. http://kns.cnki.net/ kcms/detail/.1056.R.20230908.1205.004. html.
|
32. |
李才茂. 外周血淋巴细胞和单核细胞比值对三阴性乳腺癌新辅助化疗疗效的预测价值. 现代肿瘤医学, 2022, 30(5): 810-814.
|
33. |
王轩可, 程绍强. 系统免疫炎症指数对激素受体阴性乳腺癌新辅助化疗后病理完全缓解的预测价值. 现代肿瘤医学, 2022, 30(20): 3693-3697.
|
34. |
张思琪. 全身炎症反应指数预测乳腺癌新辅助化疗后病理缓解程度研究. 承德医学院, 2023, 45(10): 1079-1083.
|
35. |
周敏, 郝宇, 付萍, 等. 中国女性成年期体质量指数及增重量与肥胖相关乳腺癌风险标志物的关联研究. 四川大学学报(医学版), 2023, 54(5): 978-984.
|
36. |
王心, 胡伟国, 宋启斌. 肥胖与乳腺癌发病相关性的研究进展. 肿瘤学杂志, 2021, 27(12): 986-990.
|
37. |
杨海梅, 刘相良, 杨晓强, 等. 肥胖对乳腺癌发生发展、治疗和预后影响的研究进展. 山东医药, 2020, 60(15): 103-106.
|
38. |
王艳莉, 方玉, 辛晓伟. 202例乳腺癌患者营养状况调查. 中国肿瘤临床与康复, 2014, 21(12): 1516-1518.
|
39. |
Liao CK, Yu YL, Lin YC, et al. Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis. World J Surg Oncol, 2021, 19(1): 139. doi: 10.1186/s12957-021-02253-y.
|
40. |
McMillan DC, Watson WS, O’Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer, 2001, 39(2): 210-213.
|
41. |
Cengiz O, Kocer B, Sürmeli S, et al. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit, 2006, 12(6): CR240-CR247.
|
42. |
Laursen I, Briand P, Lykkesfeldt AE. Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res, 1990, 10(2A): 343-351.
|
43. |
Sonnenschein C, Soto AM, Michaelson CL. Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells. Steroid Biochem Mol Biol, 1996, 59(2): 147-154.
|
44. |
Izuegbuna OO, Olawumi HO, Olatoke SA, et al. An evaluation of inflammatory and nutritional status of breast cancer outpatients in a tertiary hospital in Nigeria. Nutr Cancer, 2022, 74(1): 90-99.
|
45. |
Ugel S, Canè S, De Sanctis F, et al. Monocytes in the tumor microenvironment. Annu Rev Pathol, 2021, 16: 93-122.
|
46. |
袁茂林, 韩琼, 吴斌. 外周血淋巴细胞和单核细胞比值与乳腺癌新辅助化疗疗效关联性. 中华肿瘤防治杂志, 2020, 27(4): 283-287.
|
47. |
Chittezhath M, Dhillon MK, Lim JY, et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity, 2014, 41(5): 815-829.
|
48. |
张嘉雯, 龚予希, 白茹梦, 等. 三阴型乳腺癌中肿瘤相关巨噬细胞的临床作用及价值. 临床与实验病理学杂志, 2023, 39(3): 336-338.
|
49. |
Zhang M, Zhang H, Tang F, et al. Doxorubicin resistance mediated by cytoplasmic macrophage colony-stimulating factor is associated with switch from apoptosis to autophagic cell death in MCF-7 breast cancer cells. Exp Biol Med (Maywood), 2016, 241(18): 2086-2093.
|
50. |
Ajabnoor GM, Crook T, Coley HM. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis, 2012, 3(1): e260. doi: 10.1038/cddis.2011.139.
|